for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novartis AG

NOVN.S

Latest Trade

74.72CHF

Change

-1.85(-2.42%)

Volume

4,805,409

Today's Range

74.43

 - 

75.43

52 Week Range

74.43

 - 

86.92

As of on the SIX Swiss Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
76.57
Open
75.14
Volume
4,805,409
3M AVG Volume
79.36
Today's High
75.43
Today's Low
74.43
52 Week High
86.92
52 Week Low
74.43
Shares Out (MIL)
2,237.09
Market Cap (MIL)
181,899.90
Forward P/E
12.78
Dividend (Yield %)
4.01

Next Event

Novartis AG at Redburn CEO Conference (Virtual)

Latest Developments

More

Molecular Partners Provides Update from ACTIV-3 Global Clinical Study of Ensovibep in Patients Hospitalized with COVID-19

Novartis: Cosentyx Reduces Flare Risk 72% Versus Placebo

Novartis Iptacopan Meets Primary Endpoints In Phase Ii Study In Rare Kidney Disease C3 Glomerulopathy (C3g)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Novartis AG

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Industry

Major Drugs

Contact Info

Lichtstrasse 35

4056

Switzerland

+41.61.3241111

https://www.novartis.com/

Executive Leadership

Joerg Reinhardt

Independent Non-Executive Chairman of the Board

Vasant Narasimhan

Chief Executive Officer, Member of the Executive Committee

Enrico Vanni

Lead Independent Non-Executive Vice Chairman of the Board

Harry Kirsch

Chief Financial Officer, Member of the Executive Committee

Steven Baert

Chief People & Organization Officer, Member of the Executive Committee

Key Stats

2.31 mean rating - 29 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

51.9K

2019

47.4K

2020

48.7K

2021(E)

52.3K
EPS (USD)

2018

5.150

2019

5.400

2020

5.780

2021(E)

6.331
Price To Earnings (TTM)
18.63
Price To Sales (TTM)
3.76
Price To Book (MRQ)
3.19
Price To Cash Flow (TTM)
12.68
Total Debt To Equity (MRQ)
60.32
LT Debt To Equity (MRQ)
43.53
Return on Investment (TTM)
10.39
Return on Equity (TTM)
7.82

Latest News

Latest News

Roche shareholders approve deal to buy Novartis's $20.7 billion stake

Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.

Roche shareholders approve deal to buy Novartis's stake

Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.

EQT, BioNTech investor consider bid for Novartis arm Sandoz -report

Investment group EQT and the Struengmann family, who are investors in BioNTech, are considering a joint offer for Sandoz, the generics arm of Swiss drugmaker Novartis, Handelsblatt reported on Friday.

Roche chairman sees greater flexibility after Novartis deal - paper

Roche's $20.7 billion move to buy back nearly a third of its voting stock from fellow Swiss drugmaker Novartis will give it more strategic flexibility, Chairman Christoph Franz said in an interview published on Saturday.

Roche controlling family won't have to make offer after Novartis deal

Roche's family owners have been saved from having to make an expensive offer for the rest of the pharmaceuticals giant's shares after its $20.7 billion deal to buy back Novartis's stake took them over a voting threshold.

Roche says controlling family won't have to make offer to other shareholders

Roche said on Friday that its controlling family will be exempt from having to make an offer to other shareholders after the drugmaker's $20.7 billion deal to buy back Novartis's nearly one third voting stake.

Novartis cuts uneasy 20-year ties to Roche with $20.7 billion voting stake sale

Novartis AG said on Thursday it would sell its nearly one-third voting stake in Roche back to its cross-town rival for $20.7 billion, disentangling the two competitors that had been linked by the investment for more than two decades.

Novartis sells its Roche stake to Roche for $20.7 bln

Novartis AG and Roche said on Thursday they agreed a bilateral transaction for a sale of Roche bearer shares held by Novartis to Roche for a total consideration of $20.7 billion.

Novartis may divest generic unit Sandoz as price pressures mount

Novartis has raised the prospect of divesting its generic drugs unit Sandoz after years of revamping the business, as price pressures mount in the off-patent drug sector.

Novartis more bullish on Cosentyx, Entresto sales as Q3 profit rises

Novartis's third-quarter adjusted operating profit rose 10% as the Swiss drugmaker lifted its peak sales estimate for its two most important pharmaceuticals.

Novartis lung cancer drug fails another Phase III trial

Novartis said on Monday its canakinumab drug had failed in another trial, missing targets to improve overall survival rates for lung cancer patients and prevent the progression-free survival of people with the condition.

Novartis extends deal to make Pfizer/BioNTech vaccines

Novartis has agreed to expand its fill-and-finish support for the Pfizer/BioNTech COVID-19 vaccine by using manufacturing facilities Ljubljana, Slovenia, to fill at least 24 million doses in 2022, the Swiss drugmaker said on Thursday.

Novartis buys gene therapy firm Arctos Medical in vision loss treatment push

Swiss drugmaker Novartis said on Tuesday it has bought gene therapy specialist Arctos Medical for an undisclosed amount, aiming to boost its efforts to find treatments for severe vision loss.

Novartis halts study of iscalimab in kidney transplant patients

Novartis has halted a clinical trial of CFZ533 (iscalimab) in kidney transplant patients after interim data showed it was not as good as tacrolimus-based treatment in preventing organ rejection, the Swiss group said on Friday.

Novartis signs deal with Britain's NHS for new cholesterol drug Leqvio

Novartis AG said on Wednesday it had agreed a deal with Britain's healthcare service provider for use of the drugmaker's new anti-cholesterol drug Leqvio, after the country's healthcare cost agency NICE approved the medicine.

Novartis's Kymriah does not meet primary endpoint in late-stage study

Novartis said its Kymriah CAR-T therapy did not meet its primary endpoint of event-free survival in a phase III study in patients with aggressive B-cell non-Hodgkin lymphoma (NHL) after relapse or lack of response to first-line treatment.

Novartis's Kymriah does not meet primary endpoint in phase III study

Novartis ag said its Kymriah to treat aggressive B-cell non-Hodgkin lymphoma (NHL) after relapse or lack of response to first-line treatment did not meet its primary endpoint of event-free survival in a phase III study.

Novartis to launch new Zolgensma trial after FDA lifts restriction

Novartis will launch a new phase three study to expand the use of Zolgensma - the world's most expensive one time therapy at $2.1 million per patient treatment - after the U.S. regulator lifted its restrictions.

Novartis profit tops expectations as pandemic impact ebbs

Swiss drugmaker Novartis beat second-quarter sales and profit expectations on Wednesday, while keeping its 2021 guidance unchanged, as disruption from the coronavirus pandemic waned.

Novartis set to deliver 50 million CureVac COVID-19 vaccines this year

Novartis is still helping CureVac make COVID-19 vaccines and could expand its capacity to assist other vaccine manufacturers as well, finance chief Harry Kirsch told reporters on Wednesday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up